カナダの医療用マリファナ市場

新興の成長産業

カナダの医療用マリファナの近代史

MMAR vs. MMPR

MMARが見直された理由

MMPRの目的

医療用マリファナの規制

差し止め命令

患者用の合理化

MMPRによる処方プロセス

出荷/梱包要件

MMPRによるライセンスプロセス、他

企業プロファイル

図表

目次

The objective of this report is to provide a detailed analysis of the global market for Medical Marijuana. It is also to provide a comprehensive analysis of the leading companies producing these products, as well as the competitive environment they operate in. Marijuana (cannabis) remains a controversial drug in the twenty-first century. However, the potential role of specific cannabinoids for medical benefits will be revealed as the twenty-first century matures.

Marijuana is the most widely cultivated illicit drug plant worldwide. The international legal framework on drug control is provided by three United Nations Conventions, which instruct countries to limit drug supply and use to medical and scientific purposes. Nevertheless, there continues to be increasing debate over decriminalization, or even legalization of cannabis in particular.

This report provides an estimate of global cannabis production both in volume and value during the 2015-2020 period. The illicit use of marijuana dwarfs the medical use and that probably always will be the case. But to put global cannabis production in perspective, it is bigger than retail sales of all OTC (over-the-counter) analgesic pharmaceuticals by a factor of 9 and sales of pain medication pharmaceuticals by a factor of 25.

23 U.S. states and the District of Columbia now have legalized medical marijuana, and two states (Colorado and Washington state) allow for adult use (commonly referred to as recreational use). However, the focus in this report is on the Canada medical marijuana market, which is a new, emerging growth industry. The medical marijuana space in Canada, which went into effect in April 2014, has created conditions for a new highly regulated commercial industry with a limited amount of suppliers vetted extensively by Health Canada. Over $100 million in investment dollars have flowed into the Canadian medical marijuana industry already.

The future of medical marijuana lies in pharmaceutical products for the management of neuropathic pain, hypertension, post-stroke neuroprotection, multiple sclerosis, epilepsy, cancer, and other disorders.